LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
32.63
+2.35 (7.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Evert Schimmelpennink |
Contact Details
Address: 445 Marine View Avenue, Suite 320 Del Mar, California 92014 United States | |
| Phone | (858) 925-7000 |
| Website | lenz-tx.com |
Stock Details
| Ticker Symbol | LENZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001815776 |
| ISIN Number | US52635N1037 |
| Employer ID | 84-4867570 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary and Director |
| Shawn Olsson | Chief Commercial Officer |
| Marc G. Odrich M.D. | Chief Medical Officer |
| James W. McCollum | Co-Founder and Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Domenick Porfidia | Vice President of Sales |
| David Murphy | Vice President of Marketing |
| Breianna Bowen | Vice President of Human Resources |
| Marvin J. Garrett | Senior Vice President of Regulatory and Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 6, 2024 | 424B3 | Prospectus |
| Nov 6, 2024 | 424B3 | Prospectus |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | 8-K | Current Report |
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 28, 2024 | 8-K | Current Report |
| Sep 19, 2024 | EFFECT | Notice of Effectiveness |